Medicare Advantage与按服务付费心衰住院患者医疗质量与结局比较
该回顾性队列研究纳入Get With the Guidelines-Heart Failure登记中262 626例心衰住院患者,其中93 549例(35.6%)参加Medicare Advantage(MA),169 077例(64.4%)参加按服务付费(FFS)Medicare。调整后,两类保险患者在循证β受体阻滞剂、出院时ACEI/ARB/ARNI、左心室功能测量及出院后预约等4项心衰达标措施上无统计学显著差异;MA患者出院直接回家的比值更高(AOR 1.16;95%CI 1.13-1.19;P<.001),4天内出院比值更低(AOR 0.97;95%CI 0.93-1.00;P=.04),院内死亡无显著差异(AOR 0.98;95%CI 0.92-1.03;P=.42)。
要点
- MA与FFS心衰住院患者在4项心衰达标措施上无统计学显著差异。
- MA患者出院直接回家比值更高(AOR 1.16),4天内出院比值更低(AOR 0.97)。
- 两组院内死亡无显著差异(AOR 0.98;95%CI 0.92-1.03;P=.42)。
核心结论
- 在心衰住院患者中,MA与FFS Medicare在医疗质量或院内死亡率方面未见明显获益,仅MA患者急性期后机构使用较少。
- 随着MA持续扩张,需确保参与私人计划为参保患者提供附加价值,以证明其相对传统FFS Medicare更高管理成本的合理性。
研究设计与样本
- 观察性、回顾性队列研究,纳入参与Get With the Guidelines-Heart Failure登记的医院中心衰住院患者。
- 共262 626例心衰住院患者,其中93 549例(35.6%)参加MA,169 077例(64.4%)参加FFS Medicare。
- MA组年龄中位数(四分位距)为78(70-85)岁,FFS组为78(69-86)岁。
- 年龄、性别、合并症患病率或入院时客观指标(包括生命体征和实验室值)的标准化均数差均小于10%。
主要发现
- 调整后,两类保险类型在有指征时使用循证β受体阻滞剂、出院时ACEI/ARB/ARNI、左心室功能测量及出院后预约方面无统计学显著差异。
- MA患者出院直接回家的比值高于FFS患者(AOR 1.16;95%CI 1.13-1.19;P<.001)。
- MA患者4天内出院的比值低于FFS患者(AOR 0.97;95%CI 0.93-1.00;P=.04)。
- MA与FFS患者院内死亡无显著差异(AOR 0.98;95%CI 0.92-1.03;P=.42)。
临床怎么用
- 对心衰住院患者,保险类型(MA或FFS Medicare)不应作为预判4项心衰达标措施质量或院内死亡的依据。
- MA患者出院直接回家比例更高、4天内出院比例更低,提示出院去向与住院时长管理可能存在保险相关差异。
局限性
- 为观察性、回顾性队列研究,仅纳入参与Get With the Guidelines-Heart Failure登记的医院,可能存在选择偏倚。
- 原文未报告未调整的粗结局率、其他混杂因素控制细节及随访时间范围,无法据此推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Medicare Advantage (MA), a private insurance plan option, now covers one-third of all Medicare beneficiaries. Although patients with cardiovascular disease enrolled in MA have been reported to receive higher quality of care in the ambulatory setting than patients enrolled in fee-for-service (FFS) Medicare, it is unclear whether MA is associated with higher quality in patients hospitalized with heart failure, or alternatively, if incentives to reduce utilization under MA plans may be associated with worse care. OBJECTIVE: To determine whether there are differences in quality of care received and in-hospital outcomes among patients enrolled in MA vs FFS Medicare. DESIGN, SETTING, AND PARTICIPANTS: Observational, retrospective cohort study of patients hospitalized with heart failure in hospitals participating in the Get With the Guidelines-Heart Failure registry. EXPOSURES: Medicare Advantage enrollment. MAIN OUTCOMES AND MEASURES: In-hospital mortality, discharge disposition, length of stay, and 4 heart failure achievement measures. RESULTS: Of 262 626 patients hospitalized with heart failure, 93 549 (35.6%) were enrolled in MA and 169 077 (64.4%) in FFS Medicare. The median (interquartile range) age was 78 (70-85) years for patients enrolled in MA and 78 (69-86) years for patients enrolled in FFS Medicare. Standard mean differences in age, sex, prevalence of comorbidities, or objective measures on admission, including vital signs and laboratory values, were less than 10%. After adjustment, there were no statistically significant differences in receipt of evidence-based β-blockers when indicated; angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitors at discharge; measurement of left ventricular function; and postdischarge appointments by Medicare insurance type. Patients enrolled in MA, however, had higher odds of being discharged directly home (adjusted odds ratio [AOR], 1.16; 95% CI, 1.13-1.19; P < .001) relative to patients enrolled in FFS Medicare and lower odds of being discharged within 4 days (AOR, 0.97; 95% CI, 0.93-1.00; P = .04). There was no significant difference in in-hospital mortality between patients with MA and patients with FFS Medicare (AOR, 0.98; 95% CI, 0.92-1.03; P = .42). CONCLUSIONS AND RELEVANCE: Among patients hospitalized with heart failure, no observable benefit was noted in quality of care or in-hospital mortality between those enrolled in MA vs FFS Medicare, except lower use of post-acute care facilities. As MA continues to grow, it will be important to ensure that participating private plans provide an added value to the patients they cover to justify the higher administrative costs compared with traditional FFS Medicare.
引用
- Figueroa JF, Wadhera RK, Frakt AB, et al. Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiol. 2020. PMID: 32876650. doi:10.1001/jamacardio.2020.3638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。